secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277541
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos terminates SVP Legal and VP R&D; execs receive separation payments, consulting
--------------------------------------------------------------------------------

- Melinda Lackey (SVP, Legal) and Drew Deniger (VP, R&D) terminated without cause, effective Nov 15, 2023.
- Lackey receives $180,000 separation payment; Deniger receives $182,500 separation payment.
- Lackey enters consulting agreement at $400/hour to assist with strategic alternatives review.
- Deniger agrees to cooperate on investigations and strategic alternatives for scientific assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523277541/0001193125-23-277541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523277541/d850558d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer